"Anemia and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients".
Cancer Invest
; 39(6-7): 457-465, 2021.
Article
in En
| MEDLINE
| ID: mdl-33961512
ABSTRACT
We analyzed the effect of anemia on tumor response of patients with primary invasive breast cancer (BC) receiving neoadjuvant chemotherapy (NACT). The patient collective was very homogenous; finally, 74 BC patients with identical medication and duration of NACT were enrolled. After completion of NACT, 49 patients (66.2%) had a post-NACT Hb level <12 g/dl. In the anemic group, we found a tendency of lower median tumor response compared to nonanemic patients at this time (15 versus 17 mm, retrospectively, p = 0.18). Age at diagnosis significantly correlated with the difference of Hb [before initiation - after completion of NACT] (correlation coefficient = 0.40, p < 0.001).
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Breast Neoplasms
/
Chemotherapy, Adjuvant
/
Neoadjuvant Therapy
/
Anemia
Type of study:
Observational_studies
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Middle aged
Language:
En
Journal:
Cancer Invest
Year:
2021
Document type:
Article
Affiliation country:
Austria